11 results about "Chronic hepatic" patented technology

The present invention relates to methods of producing hypoimmunogenic functional macrophages, and cell compositions comprising the same. The hypoimmunogenic functional macrophages may be polarised or unpolarised. Such cells may be useful in the treatment of diseases, e.g. inflammatory organ damage. The therapy that may be achieved by hypoimmunogenic functional macrophages is universal, and the cells do not require matching from donor to recipient. This broadens the application of cell-based therapies, in particular in patients with chronic liver fibrosis.

A method and oral composition for treating a plurality of end-stage diseases, such as end-stage renal disease, chronic kidney disease, liver cirrhosis, chronic liver failure, end-stage liver disease, cancer, congestive heart failure, pulmonary fibrosis, and chronic obstructive pulmonary disease, are disclosed. In one embodiment of the invention, the composition comprises testosterone duodecanoate.

The present invention relates to a Lycium barbarum polysaccharide peptide, a preparation method therefor and the use thereof. The Lycium barbarum polysaccharide peptide comprises monosaccharides including mannose, glucose, galactose, arabinose and xylose, has a protein content in the range of 25 wt%-40 wt%, and has a molecular weight in the range of 3-20 kDa. By means of experiments, it is verified that the Lycium barbarum polysaccharide peptide of the present application has significant amelioration and alleviation effects on the liver damage and the degree of liver fibrosis in mice with CCl4-induced chronic liver fibrosis. The Lycium barbarum polysaccharide peptide can be developed into a drug for treating liver fibrosis or into a liver health supplement.

This invention relates to the field of biomedical technology, and particularly to protein assemblies, predictive models, and applications for predicting the incidence of chronic liver diseases based on proteomics. This invention integrates Olink proteomics technology, machine learning algorithms, and a discovery-internal validation research strategy to successfully screen and validate a set of predictive models for chronic liver diseases containing 10 plasma protein biomarkers (VCAM1, CD48, NUDT5, MILR1, TNFSF8, DDAH1, IL17RB, NFASC, FCN2, and RTN4R). Through the cross-integration of systems biology and artificial intelligence technologies, this invention develops a new approach to full-cycle prediction from early disease screening to dynamic risk monitoring, providing an innovative solution for the precise prevention and control of chronic liver diseases.

Disclosed is a method and oral composition for treating a plurality of End stage diseases such as end-stage renal disease, chronic kidney disease, liver cirrhosis, chronic liver failure, end stage liver disease, Cancer, congestive Heart failure, pulmonary fibrosis, chronic obstructive pulmonary disease. In an embodiment of the invention, the composition comprises testosterone duodecanoate.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of 1-methylnicotinamide (1-MNA) in preparation of a medicine for treating chronic liver diseases, in particular to a medicine for treating hepatic fibrosis. In order to solve the problems of poor batch stability and uniformity of cell preparations in treatment of hepatic fibrosis by MSCs at present, the active micromolecule 1-MNA derived from MSCs is screened out by analyzing metabolism and secretion components of MSCs for the first time, and it is found that the micromolecule can effectively inhibit carbon tetrachloride-induced hepatic fibrosis of mice. 1-MNA belongs to endogenous small molecules, can be synthesized in a large scale in a chemical mode, is easy to obtain, has the effect equivalent to that of MSCs transplantation treatment, and is safer and more economical.

The invention discloses an establishment method and application of a type-1 autoimmune hepatitis mouse model, and relates to the technical field of biology, and the technical key points are as follows: an adenovirus is combined with an overexpression Sepsecs plasmid to realize continuous expression of autoantigen in the liver, a chronic liver inflammation model conforming to type-1 AIH characteristics is successfully induced in a mouse body for the first time, and the mouse model has a good application prospect. The model shows clinical pathological characteristics of continuous infiltration of inflammatory cells, abnormal liver function, autoantibody generation, hepatic tissue fibrosis and the like, and has good stability and repeatability. At present, no type 1 AIH mouse model constructed by using the Sepsecs antigen is publically reported at home and abroad, and the technical blank in the field of type 1 AIH chronic animal models is filled. The model can be used for AIH pathogenesis research, autoantigen screening, novel diagnostic marker discovery, immune intervention means evaluation and clinical verification before new medicine, has wide scientific research and industrial application prospects, and provides an ideal experimental animal model platform.

The invention belongs to the technical field of traditional Chinese medicine preparation, and particularly relates to a liver-protecting traditional Chinese medicine composition which is prepared from the following raw material medicines in parts by weight: 10-15 parts of poria cocos, 8-12 parts of pericarpium citri reticulatae, 5-10 parts of sedum sarmentosum, 3-6 parts of schisandra chinensis, 2-5 parts of scorched hawthorn fruit, 2-5 parts of hypericum perforatum, 2-5 parts of fried medicated leaven, 4-8 parts of sweet-scented osmanthus and 2-4 parts of amomum cardamomum. According to the scheme, the serum ALT and AST levels of a carbon tetrachloride induced liver injury model mouse can be remarkably reduced, the pathological injury of liver tissue is relieved, the liver protection effect in an NAFLD mouse model is remarkable, and the preparation method has the advantages of being stable in preparation process and exact in curative effect. The traditional Chinese medicine composition is suitable for acute and chronic abnormal liver functions caused by various reasons, the formula follows the medication principle of liver diseases, liver awareness and spleen transmission and when the spleen is solid, and the liver protection effect is enhanced by adding the medicine for regulating the spleen and the stomach on the basis of the medicine for regulating the liver and adding the medicine for regulating the spleen and the stomach.

The purpose of the present invention is to achieve quantitative and reliable diagnosis of liver fibrosis. Provided is a diagnostic system for chronic fibrotic liver disease, used for diagnosing or assisting in the diagnosis of a degree of chronic liver fibrosis. A diagnostic result is obtained by means of detecting tertiary lymphoid structures in a patient's liver. The system comprises: an image forming apparatus, used for imaging a stained sample of liver tissue of a patient, to obtain a sample image; and an image analysis apparatus, used for analyzing the sample image, to obtain an analysis result of tertiary lymphoid structures in the patient's liver, and further deriving a diagnostic result based on the analysis result of the tertiary lymphoid structures.

Disclosed are methods and oral compositions for treating a variety of end-stage diseases, such as end-stage kidney disease, chronic kidney disease, cirrhosis, chronic liver failure, end-stage liver disease, cancer, congestive heart failure, pulmonary fibrosis, chronic obstructive pulmonary disease. In the embodiment of the invention, the composition comprises testosterone ester dodecanoate.

The invention relates to the technical field of biological medicine, in particular to a proteome-based protein combination for chronic liver disease incidence prediction, a prediction model and application. According to the invention, an Olink proteomics technology, a machine learning algorithm and a discovery-internal verification research strategy are integrated, and a group of chronic liver disease prediction models containing 10 plasma protein markers (VCAM1, CD48, NUDT5, MILR1, TNFSF8, DDAH1, IL17RB, NFASC, FCN2 and RTN4R) are successfully screened and verified. Through cross fusion of system biology and artificial intelligence technology, a new thought of full-period prediction from early disease screening to dynamic risk monitoring is developed, and an innovative scheme is provided for accurate prevention and control of chronic liver diseases.